The GLP-1 revolution that began with semaglutide (Ozempic, Wegovy) and accelerated with tirzepatide (Mounjaro, Zepbound) is about to enter a third phase — one that may leave both predecessors behind. Retatrutide, Eli Lilly's investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, produced 24.2% mean body weight reduction at 48 weeks in Phase II trials — the highest weight loss ever achieved with a pharmacological agent in a randomized controlled trial. The Phase III TRIUMPH program began enrollment in early 2025, with top-line results expected in late 2026.
Three Receptors, Three Mechanisms
Understanding why retatrutide might outperform tirzepatide (a dual GLP-1/GIP agonist) requires understanding what the glucagon receptor adds:
- GLP-1 receptor activation: Reduces appetite, slows gastric emptying, stimulates insulin secretion. The core mechanism of semaglutide.
- GIP receptor activation: Enhances insulin secretion, reduces food intake (at pharmacological doses), and improves insulin sensitivity. Adds ~5–7% additional weight loss beyond GLP-1 alone, as demonstrated by tirzepatide vs semaglutide head-to-head data.
- Glucagon receptor activation: Increases energy expenditure, promotes lipolysis, and enhances fat oxidation in the liver. By itself, glucagon receptor activation increases blood sugar — but when combined with GLP-1 and GIP (which lower blood sugar), the energy-expenditure benefits can be captured without hyperglycemia. This is the key insight behind the triple agonist approach.
Phase II Results: The 24.2% Number in Context
The Phase II TRIUMPH-A trial enrolled 338 adults with obesity (BMI ≥30 or ≥27 with comorbidities) without diabetes, randomizing to retatrutide 1, 4, 8, or 12 mg weekly or placebo. Published in NEJM in June 2023:
- 12 mg/week (highest dose) at 48 weeks: Mean weight loss 24.2% vs 2.1% placebo
- 8 mg/week: 17.3% weight loss
- 4 mg/week: 8.7% weight loss
- 83% of patients at the 12 mg dose achieved ≥15% weight loss (vs 0% placebo)
- 57% achieved ≥20% weight loss — territory previously reserved for bariatric surgery
For comparison, semaglutide 2.4 mg (Wegovy) produces ~15% weight loss and tirzepatide 15 mg produces ~21% — making retatrutide approximately 3–6 percentage points more potent at equivalent durations.
Metabolic Benefits Beyond Weight
Retatrutide produced significant improvements in cardiometabolic markers at 48 weeks:
- Fasting glucose: −17 mg/dL
- Triglycerides: −42%
- LDL: −16%
- Systolic BP: −8 mmHg
- ALT (liver enzyme): −38% — relevant for MASH (metabolic steatohepatitis)
The glucagon receptor component appears to drive particularly potent hepatic fat reduction, making retatrutide an especially promising candidate for MASH — where the FDA recently approved resmetirom (Rezdiffra) as the first drug therapy.
Safety Profile
The adverse event profile mirrors the GLP-1 class: nausea (65%), vomiting (27%), diarrhea (22%), constipation (19%) — all primarily during dose escalation and typically resolving by week 12. No new safety signals beyond the GLP-1 class were identified, including no hepatotoxicity despite glucagon receptor activation.
The TRIUMPH Phase III Program
The TRIUMPH program includes five Phase III trials:
- TRIUMPH-1: Obesity without diabetes (N=2,400)
- TRIUMPH-2: Type 2 diabetes (N=1,800)
- TRIUMPH-3: MASH (N=900)
- TRIUMPH-4: Cardiovascular outcomes (N=12,000)
- TRIUMPH-5: OSA (N=800)
If TRIUMPH-1 confirms the Phase II efficacy signal, regulatory submission is expected in mid-2027, with potential approval in early 2028.
Conclusion
Retatrutide represents the next evolution of an already-revolutionary drug class. If Phase III confirms 24% weight loss as a class effect, the pharmacological approach to obesity will have closed most of the gap with bariatric surgery — without anesthesia, anatomical rerouting, or lifelong surgical complications. The obesity medicine landscape of 2028 will look fundamentally different from 2023. Healthcare facilities can find relevant nutritional products in our catalog.
